Stolen Chloroplasts and the Chrysalis of Complex LifeĀ 

A chrysalis is one of the most familiar, yet cryptic, transformations in nature. We know what goes in. We know what comes out. For a long time, what happened in between was essentially invisible to us. Not because we weren’t curious, but because the mechanism was sealed inside something the size of a thumbnail, and we had no way in.

This same invisibility exists on a much older and much larger scale.

Sometime around two billion years ago, a cell swallowed a bacterium and, instead of digesting it, kept it alive inside itself. This process, called endosymbiosis, is arguably the single most consequential event in the history of complex life. The bacterium became a permanent resident, and over billions of years of co-evolution, it became something else entirely: the mitochondria that power every complex cell on earth. Without it, the living world as we know it doesn’t exist.

Scientists have known for decades that this kind of cellular acquisition had to have occurred. What has proved harder to explain is not that it happened, but how it started. What did the earliest molecular steps actually look like from the inside?

In the ocean, there is a microscopic single-celled organism called Rapaza viridis. It hunts algae by propelling itself through the water on whip-like appendages called flagella. That hunt may be showing us the beginning of a modern endosymbiosis: the same process that gave every complex cell its mitochondria and every plant its chloroplasts.

Continue reading “Stolen Chloroplasts and the Chrysalis of Complex LifeĀ “

Before the First Dose

Kierkegaard observed that one of humanity’s enduring tensions is that while life can only be understood backwards, it must be lived forwards. It’s a truth medicine knows intimately: in the treatment that worked until it didn’t, the resistance that arrived without warning, the moment a doctor has to tell a patient that the drug that was helping has stopped. Not because anyone made a mistake, but because the critical knowledge that would have mattered arrived too late, if at all.

A recent paper from the National Cancer Institute is, in a small but meaningful way, science’s pursuit of that elusive foresight: an understanding that emerges early enough, for once, to change what happens next.

The Elegant Idea

For decades, chemotherapy has worked by brute force, flooding the body with toxins designed to kill rapidly dividing cells. The problem is that rapid division isn’t unique to cancer. Hair follicle cells, gut lining cells and immune cells also divide rapidly, which is why patients lose hair, lose energy and become susceptible to infection. Chemotherapy targets a behavior, but the drug has no way to tell a healthy cell from a cancerous one.

Antibody-drug conjugates (ADCs) change that. Instead of targeting what cancer cells do, they target what cancer cells are. Cancer cells tend to display certain proteins on their surface in far greater numbers than healthy cells do. The antibody is engineered to seek out those proteins specifically. It navigates to its target, binds and waits for the cell to do what cells routinely do: pull it inside. Once there, the cell’s own digestive machinery (the lysosome) breaks down the chemical tether holding the toxin to the antibody, releasing the toxin to kill the cell from within. More than a dozen ADCs have received FDA approval in recent years, and the field is evolving fast.

What the Cell Does Next

But cancer cells don’t simply accept their fate. Even when an ADC delivers its payload perfectly—the antibody finds its target, the cell pulls it inside, the lysosome cuts the tether—a pump embedded in the cell membrane can grab the released toxin and throw it back out before it causes damage.

The delivery worked. The package got ejected anyway.

These pumps—ATP-binding cassette transporters, or more plainly, efflux pumps—are a normal feature of cell biology. Their job is cellular housekeeping, clearing out unwanted or toxic substances before they cause damage. Under the pressure of drug treatment, cancer cells do what life has always done under pressure: the ones best equipped to survive do. The same mechanism that has shaped living things for billions of years now works against the treatment. Not all cancer cells are identical, and the ones that happen to produce more pumps survive while others don’t, gradually shifting the tumor toward resistance.

Continue reading “Before the First Dose”

Light Has a Favorite Color, But It’s Complicated

Last spring, my niece and I made a trip to a home improvement store to put together a Mother’s Day planter for my sister. My niece had a clear vision: my sister’s favorite color is blue, so we were going to buy blue flowers. We walked every aisle of the garden center. We checked the annuals, the perennials, and the hanging baskets then left with purple, red, and a grumpy 7-year-old.

It turns out we were not up against a bad selection. We were up against biology.

The Problem with Blue

Blue is one of the rarest colors in the natural world. The food industry is currently finding that out the hard way. There is a good chance you have eaten something blue today. Maybe it was the frosting on a birthday cake, the coating on some M&M’sĀ® candies, or the sports drink in your refrigerator. That blue almost certainly came from a petroleum-based synthetic dye, and for the first time in decades, the food industry is being asked to find something better.

The FDA banned Red Dye No. 3 in January 2025, and pressure has been building around the remaining synthetic dyes ever since, including Blue No. 1 and Blue No. 2. Major food brands have begun announcing plans to reformulate.

There is just one problem. Blue is genuinely, stubbornly hard to make in nature. It turns out that blue has almost nothing to do with color, and almost everything to do with light.

Continue reading “Light Has a Favorite Color, But It’s Complicated”

A Live-Cell NanoBRET Assay Shines Light on Toxic RNA–Protein Interactions in Myotonic Dystrophy

How NanoBRET works image.

RNA doesn’t just carry genetic instructions—it also interacts with proteins to regulate nearly every aspect of gene expression, from splicing to translation. When those interactions go awry, the consequences can be devastating. In myotonic dystrophy type 1 (DM1), the most common adult-onset muscular dystrophy, a toxic RNA repeat expansion hijacks a critical protein called MBNL1, trapping it in nuclear clumps called foci. This leads to widespread splicing defects and progressive muscle wasting. But studying these toxic interactions inside living cells—and finding small molecules that can disrupt them—has been a significant challenge.

A recent study led by the Scripps Institute may have a solution. The study introduces a NanoBRETā„¢ assay that can monitor the interaction between the expanded CUG RNA repeats and MBNL1 protein in real time, in live cells. Their findings demonstrate how this platform can be used not only to detect disease-driving RNA–protein complexes but also to identify small molecules that break them apart.

Continue reading “A Live-Cell NanoBRET Assay Shines Light on Toxic RNA–Protein Interactions in Myotonic Dystrophy”

From Gum Disease to Breast Cancer: An Oral Bacterium’s Unexpected Journey

You’re sitting in the dentist’s chair, nodding along to the familiar flossing lecture you’ve been politely ignoring for most of your adult life. Fair enough. It’s hard to get excited about gum health. But it turns out your dentist may have been underselling the pitch.

A study published in January 2026 in Cell Communication and Signaling shows that a common gum disease bacterium can promote breast cancer growth and spread in mice, and the findings hint at a particularly troubling link for people carrying BRCA1 mutations (1). “Floss to help prevent cancer” probably wasn’t on your 2026 bingo card, yet here we are.

Continue reading “From Gum Disease to Breast Cancer: An Oral Bacterium’s Unexpected Journey”

Life on Mars? Proteomic Secrets of Bacterial Survival in Martian Brines

Could bacteria survive on Mars? While images of the red planet might spark thoughts of barren landscapes and lifeless deserts, Mars holds a fascinating possibility: under suitable conditions, pockets of salty, perchlorate-rich brines could temporarily form on or near its surface. These brines are formed by salts that naturally absorb water from their surroundings. By lowering the temperature at which water freezes, these salts can stabilize liquid water, raising intriguing questions about the potential for microbial life. But what exactly would it take for bacteria to survive there? New research from Kloss et al. published in Scientific Reports sheds light on this cosmic question.

Continue reading “Life on Mars? Proteomic Secrets of Bacterial Survival in Martian Brines”

Promega Fc Effector Assays: Measure Every Mechanism

This post is written by Kai Hillman, PhD, Promega Corporation.

Every day, scientists push the boundaries of what’s possible with monoclonal antibodies (mAbs)—from targeting cancer cells to calming autoimmune-driven inflammation. These therapies rely not only on binding but on engineering the desired immune response. The suite of Promega Fc Effector Assays helps you understand these interactions from receptor binding and function, through bridging studies. With consistency, sensitivity, and scalability, these assays support teams from early discovery through lot release.

This article draws on real-world publications and product insights to show how Promega assays are powering next-generation immunotherapies—and redefining how we measure immune engagement.

Schematic diagramming the suite of Promega Fc effector assays in one seamless workflow to support antibody development across the pipeline.
Figure 1. Promega delivers the most comprehensive suite of Fc effector assays in one seamless workflow to support antibody development across the pipeline.
Continue reading “Promega Fc Effector Assays: Measure Every Mechanism”

What Shelter Dogs Can Tell Us About Emerging Zoonotic Diseases

Why Are Zoonotic Diseases Becoming a Bigger Risk?

As of September 9, 2025, the Worldometer listed the human global population as 8.3 billion people (1). This population growth means that humans will be living and working in previously uninhabited or minimally disturbed environments, increasing interactions between humans, domestic animals, wildlife, and their pathogens. This intensifying human-animal interface heightens the risk of zoonotic disease transmission, where pathogens cross species barriers (from wildlife to domestic livestock or from wildlife to humans), potentially leading to outbreaks and even pandemics.

How Do Urbanization and Climate Change Amplify Zoonotic Threats?

Urbanization, habitat disruption, and climate change further exacerbate these risks by altering ecosystems and facilitating the spread and emergence of vector-borne and zoonotic diseases. Understanding and addressing these threats requires robust surveillance, effective diagnostics, and proactive strategies to prevent and mitigate disease emergence and spread.

In urban areas, public health officials are already using wastewater to monitor known pathogens and identify ā€œhot spotsā€ of activity to predict increases in illness within local populations (2). Animal shelters are another place where there is an opportunity to monitor for emerging infectious diseases that could affect domestic pet animals.

Continue reading “What Shelter Dogs Can Tell Us About Emerging Zoonotic Diseases”

Polyserine Targeting: A New Strategy Against Neurodegeneration

Neurodegenerative diseases like Alzheimer’s are marked by the accumulation of misfolded proteins that wreak havoc on neurons. One of the most notorious culprits is tau, a structural protein that, in its diseased form, clumps together into aggregates that spread throughout the brain. These aggregates interfere with normal cellular processes, leading to memory loss, behavioral changes, and other devastating symptoms. Preventing tau aggregation is therefore a key strategy for slowing the progression of these symptoms.

What if we could recruit molecular ā€œhelpersā€ to stop tau from accumulating?

Continue reading “Polyserine Targeting: A New Strategy Against Neurodegeneration”

Developing an Experimental Model System to Understand the Tumor Microenvironment of Melanoma Brain Metastases

Cancer’s greatest threat is its ability to spread to other tissues—a process known as metastasis. Melanoma, a form of skin cancer, exemplifies this devastating progression. Although treatable when caught early—with surgical removal resulting in over 99% survival at five years—once melanoma metastasizes, five-year survival rates plummet dramatically to around 27%. Even more concerning, melanoma exhibits a particularly high tendency to invade the central nervous system, causing melanoma brain metastases (MBMs) that are incurable and reduce median survival to just 13 months.

To understand metastasis, we need reliable and realistic experimental models. Traditional cell cultures on plastic dishes are limited, failing to replicate the intricate spatial organization and biochemical interactions within living tissues. Animal models are informative but expensive, ethically complex, and not always accurate for human diseases. Addressing this critical gap, Reed-McBain and colleagues (2025) introduced an innovative microphysiological system (MPS) designed to simulate the tumor microenvironment in the brain affected by metastatic melanoma.

Continue reading “Developing an Experimental Model System to Understand the Tumor Microenvironment of Melanoma Brain Metastases”